| [1] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA: A Cancer Journal for Clinicians, 2011, 61(2): 69-90.
|
| [2] |
Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017 [J]. CA: A Cancer Journal for Clinicians, 2017, 67(3): 177-193.
|
| [3] |
Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline summary from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology [J]. Journal of Oncology Practice, 2017, 13(5): 333-337.
|
| [4] |
Loree JM, Pereira AAL, Lam M, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes [J]. Clin Cancer Res, 2018, 24(5): 1062-1072.
|
| [5] |
Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies [J]. Journal of Gastrointestinal Oncology, 2015, 6(6): 660-667.
|
| [6] |
Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer [J]. British Journal of Cancer, 2009, 101(3): 465-472.
|
| [7] |
Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers [J]. Oncotarget, 2017, 8(49): 86356-86368.
|
| [8] |
Tie J, Gibbs P, Lipton L, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation [J]. International Journal of Cancer, 2011, 128(9): 2075-2084.
|
| [9] |
Wang X, Wei Q, Gao J, et al. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study [J]. Chinese Journal of Cancer, 2017, 36(1): 81.
|
| [10] |
Chen D, Huang JF, Liu K, et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis [J]. PloS One, 2014, 9(3): e90607.
|
| [11] |
Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers [J]. Cancer Research, 2005, 65(14): 6063-6069.
|
| [12] |
Xu Q, Xu AT, Zhu MM, et al. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis [J]. Journal of Digestive Diseases, 2013, 14(8): 409-416.
|
| [13] |
Sinicrope FA, Shi Q, Allegra CJ, et al. Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers : A secondary analysis of 2 randomized clinical trials [J]. JAMA Oncology, 2017, 3(4): 472-480.
|
| [14] |
De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J]. The Lancet Oncology, 2010, 11(8): 753-762.
|
| [15] |
Cremolini C, Loupakis F, Masi G, et al. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials [J]. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2016, 27(5): 843-849.
|
| [16] |
Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study [J]. The Lancet Oncology, 2015, 16(13): 1306-1315.
|
| [17] |
Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis [J]. European Journal of Cancer (Oxford, England : 1990), 2015, 51(5): 587-594.
|
| [18] |
Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer [J]. British Journal of Cancer, 2015, 112(12): 1888-1894.
|
| [19] |
Kopetz S, Mcdonough SL, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406) [J]. J Clin Oncol, 2017, 35(4_suppl): 520.
|
| [20] |
Elez E, Argiles G, Tabernero J. First-line treatment of metastatic colorectal cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405 [J]. Current Treatment Options in Oncology, 2015, 16(11): 52.
|
| [21] |
Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer [J]. J Clin Oncol, 2015, 33(34): 4032-4038.
|
| [22] |
Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR [J]. Nature, 2012, 483(7387): 100-103.
|
| [23] |
Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer [J]. Cancer Research, 2012, 72(3): 779-789.
|
| [24] |
Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib [J]. Cancer Discovery, 2012, 2(3): 227-235.
|
| [25] |
Atreya CE, Van Cutsem E, Bendell JC, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin oncol, 2015, 33(suppl): a103.
|
| [26] |
Pan JH, Zhou H, Zhu SB, et al. Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer [J]. Cancer Management and Research, 2018, 10(2): 289-301.
|
| [27] |
Wang Z, Dai WP, Zang YS. Complete response with fluorouracil and irinotecan with a BRAF(V600E) and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report [J]. OncoTargets and Therapy, 2019, 12: 443-447.
|
| [28] |
Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, Encorafenib, and Cetuximab Triplet therapy for patients with BRAF V600E-Mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study [J]. J Clin Oncol, 2019, 37(17): 1460-1469.
|